内田三千彦 | 福井医科大学第一内科

スポンサーリンク

概要

関連著者

もっと見る

著作論文

新Ara-C誘導体, N4-palmitoyl-1-β-D-arabinofurasyl cytosineにより完全寛解を得た低形成性白血病の1例
Urine pH and Uric Acid Metabolism in Patients with Gout
Studies on Hyperuricemia in Gout by Inosine loading Test
Reduction of Serum Urate Level of Gouty Patients by Administration of Sobrerol and its Action Mechanism
Pharmacological studies on a new antitumor agent, N4-palmitoyl-ara-C in tumor of hematopoietic organ.
Plasma drug level maintenance and its mechanism during intravenous administration of behenoyl-arabinofuranosyl cytosine (BHAC).
タイトル無し
Uricosuric effect of zotepine and its action mechanism
タイトル無し
タイトル無し
Studies on Enzymological Abnormalities of Blood Cells obtained from a Case of 2, 8-Dihydroxyadenine Urolithiasis
Purine nucleotide biosynthesis in leukemic promyelocytes treated with retinoid
Clinical effect of rhG-CSF (KRN8601) for infectious disease in hematopoietic tumor patient.
Establishment of a daunorubicin resistance, K562 cell lines and study of its resistance mechanism.
A difference in time-dependent morphological change of L1210 cell by daunorubicin and Cytosine Arabinoside.
Incorporation and DNA damage by Cytosine arabinoside in L1210 cell.
Action mechanism of pharmacokinetics and metabolite Idarubicinol in acute leukemia patient of a new antitumor medicine, Idarubicin.
Study of action potentiation factor by Ara-C.On combined use of anthracycline.
A quantitative evaluation by image analysis equipment of L1210 alteration of cellular morphology by antitumor medicine.
Effect of ionic strength on Idarubicin-DNA complex.
Action mechanism of anthracycline series and anthraquinone series antitumor medicine riewed from binding to DNA.
Antitumor effect of Ara-C analogue of difluorodeoxytidine(dFdC) from the viewpoint of pharmacological action.
Effect of combined use of nucleoside for cellular accumulation and activation of Cytosine arabinoside.
Antitumor effect of daunorubicin,cytosine arabinoside and vincristine for L1210 leukemia cell based on the observation of dynamic changes of cell morphology.
Studies of antitumor effect of 4-carbamoylimidazolium-5-olate (SM-108) on leukemic cells and its enhancement by dipyridamole.
Studies on the optimal dosage for activation of cytosine arabinoside (ara-C).
Study of serum uric acid level lowering effect of a hyperlipidemia therapeutic agent, N-{3-(4-(2,6-dimethylheptyl)phenyl)butanoyl}ethanolamine(E5050).
Distribution of antitumor drugs in plasma and blood cells, and their pharmacokinetics.
Action mechanism of topoisomerase I inhibitor 7-ethyl-10-(4-(1-piporidino)-1-piperidino) (carbonyloxycamptothecin (CPT-11).

もっと見る

スポンサーリンク